In vitro activity of two amphotericin B formulations against Malassezia furfur strains recovered from patients with bloodstream infections - PubMed (original) (raw)
doi: 10.1093/mmy/myu089. Epub 2015 Jan 28.
Affiliations
- PMID: 25631480
- DOI: 10.1093/mmy/myu089
In vitro activity of two amphotericin B formulations against Malassezia furfur strains recovered from patients with bloodstream infections
Roberta Iatta et al. Med Mycol. 2015 Apr.
Abstract
Although guidelines for the treatment of Malassezia furfur fungemia are not yet defined, clinical data suggest that amphotericin B (AmB) is effective for treating systemic infections. In the absence of clinical breakpoints for Malassezia yeasts, epidemiological cut-off values (ECVs) are useful to discriminate between isolates with and without drug resistance. This study aimed to compare the distribution of minimal inhibitory concentration (MIC) and the ECVs for AmB of both deoxycholate (d-AmB) and liposomal (l-AmB) formulations of M. furfur isolates. The 84 M. furfur strains analyzed, which included 56 from blood, sterile sites and catheters, and 28 from skin, were isolated from patients with bloodstream infections. MICs were determined by the modified broth microdilution method of the Clinical and Laboratory Standards Institute (CLSI). The l-AmB MIC and the ECVs were two-fold lower than those of d-AmB and a lower l-AmB mean MIC value was found for blood isolates than from skin. The ECVs for l-AmB and d-AmB were 8 mg/l and 32 mg/l, respectively. Three strains (3.6%) showed l-AmB MIC higher than ECV (MIC > 8 mg/l) of which two were isolated from the catheter tip of patients treated with micafugin, l-Amb and fluconazole, and one from skin. The results showed that the l-AmB might be employed for assessing the in vitro antifungal susceptibility of M. furfur by a modified CLSI protocol and that ECVs might be useful for detecting the emergence of resistance.
Keywords: CLSI; Malassezia furfur; amphotericin B susceptibility; bloodstream infections; epidemiological cut-off.
© The Author 2015. Published by Oxford University Press on behalf of The International Society for Human and Animal Mycology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Similar articles
- Clinical data analysis of 86 patients with invasive infections caused by Malassezia furfur from a tertiary medical center and 37 studies.
Zhang X, Jin F, Ni F, Xu Y, Lu Y, Xia W. Zhang X, et al. Front Cell Infect Microbiol. 2023 Jun 29;13:1079535. doi: 10.3389/fcimb.2023.1079535. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37457952 Free PMC article. Review. - Azole susceptibility of Malassezia pachydermatis and Malassezia furfur and tentative epidemiological cut-off values.
Cafarchia C, Iatta R, Immediato D, Puttilli MR, Otranto D. Cafarchia C, et al. Med Mycol. 2015 Sep;53(7):743-8. doi: 10.1093/mmy/myv049. Epub 2015 Jul 10. Med Mycol. 2015. PMID: 26162472 - In vitro antifungal susceptibility of Malassezia furfur from bloodstream infections.
Iatta R, Figueredo LA, Montagna MT, Otranto D, Cafarchia C. Iatta R, et al. J Med Microbiol. 2014 Nov;63(Pt 11):1467-1473. doi: 10.1099/jmm.0.078709-0. Epub 2014 Aug 28. J Med Microbiol. 2014. PMID: 25168965 - Malassezia species: the need to establish epidemiological cutoff values.
Rojas FD, Sosa MLÁ, Latorre W, Mussin J, Alegre L, Giusiano G. Rojas FD, et al. Med Mycol. 2022 Aug 8;60(8):myac048. doi: 10.1093/mmy/myac048. Med Mycol. 2022. PMID: 35772016 - Candida and candidaemia. Susceptibility and epidemiology.
Arendrup MC. Arendrup MC. Dan Med J. 2013 Nov;60(11):B4698. Dan Med J. 2013. PMID: 24192246 Review.
Cited by
- In Vitro Azole and Amphotericin B Susceptibilities of Malassezia furfur from Bloodstream Infections Using E-Test and CLSI Broth Microdilution Methods.
Rhimi W, Inyang Aneke C, Mosca A, Otranto D, Cafarchia C. Rhimi W, et al. Antibiotics (Basel). 2020 Jun 26;9(6):361. doi: 10.3390/antibiotics9060361. Antibiotics (Basel). 2020. PMID: 32604712 Free PMC article. - Malassezia spp. Yeasts of Emerging Concern in Fungemia.
Rhimi W, Theelen B, Boekhout T, Otranto D, Cafarchia C. Rhimi W, et al. Front Cell Infect Microbiol. 2020 Jul 28;10:370. doi: 10.3389/fcimb.2020.00370. eCollection 2020. Front Cell Infect Microbiol. 2020. PMID: 32850475 Free PMC article. Review. - Clinical data analysis of 86 patients with invasive infections caused by Malassezia furfur from a tertiary medical center and 37 studies.
Zhang X, Jin F, Ni F, Xu Y, Lu Y, Xia W. Zhang X, et al. Front Cell Infect Microbiol. 2023 Jun 29;13:1079535. doi: 10.3389/fcimb.2023.1079535. eCollection 2023. Front Cell Infect Microbiol. 2023. PMID: 37457952 Free PMC article. Review. - Malassezia spp. and Candida spp. from patients with psoriasis exhibit reduced susceptibility to antifungals.
de Aguiar Cordeiro R, Reis AT, Lima XTV, de Andrade ARC, Aguiar ALR, Portela FVM, Pereira LMG, Moura SGB, da Silva BN, de Lima-Neto RG, Maia DCSC, Rocha MFG, Sidrim JJC. de Aguiar Cordeiro R, et al. Braz J Microbiol. 2023 Mar;54(1):169-177. doi: 10.1007/s42770-022-00883-2. Epub 2022 Dec 8. Braz J Microbiol. 2023. PMID: 36480120 Free PMC article. - Malassezia: Zoonotic Implications, Parallels and Differences in Colonization and Disease in Humans and Animals.
Hobi S, Cafarchia C, Romano V, Barrs VR. Hobi S, et al. J Fungi (Basel). 2022 Jul 4;8(7):708. doi: 10.3390/jof8070708. J Fungi (Basel). 2022. PMID: 35887463 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources